The AAO is largely supportive of the bill, S. 959, but calls for exemption from provisions that require specific patient designation for biological products and marketed drugs. The Academy argues there is no evidence linking safe repackaging processes with the use of a patient’s name when labeling a drug.
More Articles on Ophthalmology:
Dr. Judy Meyers Joins Ophthalmology Associates in Fort Worth
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
